Financing ·
Absci Corporation reported second quarter 2026 financial results and announced positive interim Phase 1 data from its…
ABSIAbsci Corp
Absci Corporation reported second quarter 2026 financial results and announced positive interim Phase 1 data from its HEADLINE trial of ABS-201, an anti-PRLR antibody for pattern hair loss. The company completed a $100 million underwritten offering, which included a $40 million strategic equity investment from Eli Lilly & Company. Cash, cash equivalents, and marketable securities totaled $201.1 million as of June 30, 2026, sufficient to fund operations into the second half of 2028. Revenue was $0.3 million, while net loss was $33.2 million for the quarter. The company anticipates reporting interim proof-of-concept data for ABS-201 in pattern hair loss in the second half of 2026 and full proof-of-concept data in early 2027. Absci is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI.